Ablynx (EBR:ABLX) ABLYNX STRENGTHENS MANAGEMENT TEAM WITH THE APPOINTMENT OF DR DEBBIE LAW AS CHIEF SCIENTIFIC OFFICER

Ablynx (EBR:ABLX) GHENT, Belgium, 8 January 2009 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has appointed Dr Debbie Law, as its Chief Scientific Officer.

Dr Law has over thirteen years experience in the biotech industry, with significant expertise in drug discovery and the successful progression of lead candidates into preclinical development. She will head up the research activities and identify and prioritise new therapeutic programmes that Ablynx will take forward to continue building its rapidly growing portfolio of Nanobody® development candidates.

Prior to joining Ablynx, Dr Law was at PDL BioPharma for five years where since 2006 she held the position of Vice President of Research. Previously she has also held senior research positions with EOS Biotechnology and COR Therapeutics.

Dr Law received her D. Phil. in immunology from the University Oxford in 1989 and followed this taking a post-doctoral position at the University of California, San Francisco.

Dr Edwin Moses, CEO and Chairman said: "We are delighted that Debbie is joining to head up the research activities at Ablynx. She brings with her a wealth of knowledge and experience in the drug discovery area with particularly strong expertise in biologics, which will further strengthen and complement our existing management team. We continue to rapidly advance our lead candidates towards the clinic and currently have two of our own Nanobodies® in clinical trials."

Commenting on her appointment, Dr Law said: "I am joining Ablynx at a tremendously exciting time and I am looking forward to contribute to the creation of a very strong Nanobody® portfolio of products. I am impressed by the broad applicability of the Nanobody® technology to different target classes and therapeutic areas. I am also excited by the possibility of advancing alternative routes of delivery of Nanobodies®."

-ends-

For more information, please contact:

College Hill Life Sciences for UK/International media enquiries: Sue Charles, Justine Lamond, Dr John McIntyre t: +44 (0)20 7866 7857 e: ablynx@collegehill.com

Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com

Eva-Lotta Allan Chief Business Officer t: +32 (0)9 262 00 75 m: +32 (0)475 78 36 21 / +44 (0)7990 570 900 e: eva-lotta.allan@ablynx.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



LINK: http://hugin.info/137912/R/1280838/286267.pdf

Ablynx

http://www.ablynx.com

ISIN: BE0003877942

Stock Identifier: XBRU.ABLX